Site Search

CF Foundation's $1 Million Investment Helped Drug Known as Cayston® Become a Reality

New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis

Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments

Galapagos and Cystic Fibrosis Foundation Therapeutics Sign €1.3 million* Agreement

Cystic Fibrosis Foundation Therapeutics to Provide Alnylam with $1.5 Million in Funding for Discovery Efforts

The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.

The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco^®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.